LIVE EVENT: The U.S. healthcare law rollout: Where do we stand?
NEW YORK - U.S. prosecutors have charged 49 current and former Russian diplomats and their family members with participating in a scheme to get health benefits intended for the poor by lying about their income.
WASHINGTON - The pregnancy rate among U.S. women fell to its lowest point in 12 years in 2009, continuing its slide from a peak in 1990, according to U.S. government data released on Thursday.
LONDON - A legal case over access to details of clinical trials held by Europe's drugs regulator - sparked by two U.S. firms wanting to keep their data secret - has been hit by delay after the EU's top court sent it back to be re-examined by a lower body.
WASHINGTON - More people signed up on the government's new health insurance website on the first two days of December than in the entire first month of the launch of President Barack Obama's healthcare reform, sources familiar with the numbers said on Wednesday.
NEW YORK (Reuters Health) - Gay teenagers who have had at least four sexual partners are at increased risk of contracting human papillomavirus (HPV), a new study suggests.
NEW YORK - Global drugmaker Pfizer Inc will broaden access to information from its scores of clinical trials to independent researchers and to patients who take part in the studies, the company said on Wednesday.
LONDON - Many governments are woefully unprepared for an epidemic of dementia currently affecting 44 million people worldwide and set to more than treble to 135 million people by 2050, health experts and campaigners said on Thursday.
- Eli Lilly and Co said on Thursday it would not seek approval for edivoxetine, its experimental drug to treat major depression, after it failed to meet its primary goal in three late-stage trials.
HONG KONG - Chinese regulators are considering cutting retail price limits on some traditional Chinese medicines (TCM) by as much as 10 percent early next year, a newspaper controlled by the official Xinhua news agency reported.
LONDON - Iceland is joining the race to make copycat versions of complex biotech drugs with an investment of $250 million in development and manufacturing by Alvotech, a sister company of privately owned U.S.-based Alvogen.
On Wednesday, December 4 at 10:30 a.m. watch live as experts assess where the U.S. stands in the healthcare law rollout and the resulting health policy implications. Presented by the forum at Harvard School of Public Health in collaboration with Reuters. Live Coverage